Bollard Group LLC Genmab A/S Transaction History

Bollard Group LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$37.4 - $42.94 $15,969 - $18,335	427 New	427 $16,000
Q1 2021 May 11, 2021	SELL	$30.92 - $44.4 $6,184 - $8,880	-200 Closed	0 $0
Q4 2020 Feb 04, 2021	BUY	$33.66 - $40.76 $6,731 - $8,152	200 New	200 $8,000
Q3 2020 Nov 12, 2020	SELL	$33.07 - $38.68 $29,101 - $34,038	-880 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$20.05 - $33.89 $17,644 - $29,823	880 New	880 $30,000

240

52.6M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $14.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Bollard Group LLC, based on Form 13F filings with the SEC.

Stay updated on Bollard Group LLC with notifications on news.